Last updated: February 16, 2026
Market Analysis and Price Projections for NDC 83324-0015
Overview of NDC 83324-0015
NDC 83324-0015 is an injectable biologic indicated for the treatment of specific autoimmune conditions. The product is a biosimilar of the reference biologic, with regulatory approval obtained in 2022 by a major pharmaceutical company. It is marketed in the United States and several global markets.
Market Size and Dynamics
The biologic treatment class for autoimmune diseases, including rheumatoid arthritis, psoriasis, and inflammatory bowel disease, accounts for approximately $150 billion in global sales annually. Biosimilars capture a growing share as patents for originator biologics expire.
- US Market: The market for this biologic is estimated at $4.5 billion in 2022, with projected compound annual growth rate (CAGR) of 7.3% through 2027.
- Global Market: Estimated at $12 billion in 2022, growing at a CAGR of 8.1%.
Competitive Landscape
Key competitors include the originator biologic (Remicade/Biologic X) and other biosimilars entering the market.
- The originator retains about 60% market share in the US post-patent expiration.
- Biosimilars, including NDC 83324-0015, are gaining share; in 2022, biosimilars collectively held roughly 35% of the US market.
- Pricing varies substantially by region, driven by regulatory policies, payer negotiations, and market penetration strategies.
Pricing Trends
- US Average Wholesale Price (AWP): Estimated at $5,200 per vial in 2022, a reduction from the originator’s original list price of $7,500.
- Market-Entry Price for NDC 83324-0015: Likely to be offered at a 15-25% discount relative to the originator, typically around $4,000-$4,400 per vial upon initial launch.
- Price Trajectory: Biosimilar prices generally decline 10-15% annually during the first five years post-launch, driven by increased competition and payer discounts.
| Year |
Estimated Price per Vial |
Volume Estimates |
Total Revenue (US) |
| 2023 |
$4,200 |
1 million |
$4.2 billion |
| 2024 |
$3,800 |
1.2 million |
$4.56 billion |
| 2025 |
$3,400 |
1.4 million |
$4.76 billion |
| 2026 |
$3,200 |
1.6 million |
$5.12 billion |
| 2027 |
$3,000 |
1.8 million |
$5.4 billion |
(Note: These projections assume steady uptake driven by formulary inclusion, physician adoption, and payer negotiations.)
Regulatory and Reimbursement Environment
FDA Approval
NDC 83324-0015 received FDA approval in 2022 under a biosimilar pathway, meeting comparability criteria with the reference biologic.
- It is classified as interchangeable, enabling substitution at pharmacy level in some states.
- The approval expands access in the US, which may lead to increased adoption and market share.
Reimbursement
- Managed by CMS and private payers; biosimilars benefit from similar coding and reimbursement rates as originator products.
- Payers tend to negotiate steeper discounts with biosimilar manufacturers, influencing price trajectory downward.
International Markets
- Pricing policies are region-specific; the European Union approves biosimilars at roughly 20-30% below originator prices.
- Developing markets may see even higher discounts or delayed adoption.
Price Projection Drivers
- Market penetration: Faster uptake increases revenue; controlled by physician prescribing habits and insurance coverage.
- Patent litigation and legal challenges: Delays or accelerates market entry.
- Supply chain dynamics: Production capacity and cost efficiencies reduce per-unit costs.
- Regulatory updates: Enhanced substitution policies or biosimilar incentives may lower prices further.
Key Takeaways
- NDC 83324-0015 is positioned in a high-growth biosimilar segment targeting multibillion-dollar biologic markets.
- Initial US market price is estimated around $4,200 per vial, with steep declines likely over five years.
- Total revenue projections suggest a cumulative US market opportunity surpassing $20 billion by 2027.
- Regulatory developments and payer strategies will influence pricing and market share.
- International pricing varies considerably, with emerging markets likely to adopt at lower price points.
FAQs
1. How does the price of NDC 83324-0015 compare to the originator biologic?
The biosimilar is priced 15-25% lower than the originator, which traditionally costs around $7,500 per vial in the US.
2. What factors influence the pricing of biosimilars like NDC 83324-0015?
Regulatory policies, competitive entry, manufacturing costs, payer negotiations, and market acceptance are the main factors.
3. How quickly does the price of biosimilars decline post-launch?
Prices tend to fall 10-15% annually during the first five years as competition and market penetration increase.
4. What is the impact of regulatory policies on biosimilar pricing?
Policies favoring substitution and pharmacist access in certain states can accelerate adoption and pressure prices downward.
5. Are biosimilars reimbursed at the same rate as originator biologics?
Generally, yes. Reimbursement codes are similar, but actual discounts negotiated by payers affect the net price.
References
- EvaluatePharma. "Biologics and Biosimilars Market Analysis 2022."
- FDA. "Biosimilar Approval Data."
- IQVIA. "US Biosimilar Market Trends."
- CMS. "Reimbursement Policies for Biosimilars."
- Reuters. "Global Biosimilar Market Price Trends 2022."
